Primary Site >> Pancreatic Cancer

Gene >> PTPRF

  • 1997
  • 2001
  • 2002
  • 2005
  • 2006
  • 2007
  • 2011
  • 2012
  • 2014
  • 2015
  • 2016
  • 2018
Ref: Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
PMID: 9825482
Ref: Endosonography is superior to angiography in the preoperative assessment of vascular involvement among patients with pancreatic carcinoma.
PMID: 11154172
Ref: [Clinical response of an atypical glucagonoma treated with a long-acting somatostatin analog].
PMID: 12434103
Ref: Phase II study of gemcitabine plus 5-fluorouracil biologically modulated by folinic acid plus long-acting formulation of octreotide (LAR) in patients with advanced pancreatic cancer.
PMID: 17357189
Ref: Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2.
PMID: 16479142
Ref: Medical treatment of benign insulinoma using octreotide LAR: a case report.
PMID: 17124362
Ref: Rheumatoid arthritis associated with the use of Sandostatin(R) LAR(R) depot in a patient with pancreatic neuroendocrine tumor. An association or a coincidence? The first case report.
PMID: 21737909
Ref: Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.
PMID: 23102680
Ref: Elderly patients with pancreatic cancer.
PMID: 25076333
Ref: Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
PMID: 25688512
Ref: Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs.
PMID: 25689143
Ref: Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.
PMID: 26126727
Ref: [Treatment Strategy for Non-Functional Pancreatic Neuroendocrine Tumors (P-NETs) at Kurume University Hospital].
PMID: 26809536
Ref: 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer.
PMID: 29590448
Ref: Lactic dehydrogenase to albumin ratio in prediction of unresectable pancreatic cancer with intervention chemotherapy.
PMID: 29848124
Ref: Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors.
PMID: 30057604